Browse our anti-AZGP1 (AZGP1) Antibodies

Mouse (Murine) alpha-2-Glycoprotein 1, Zinc-Binding (AZGP1) interaction partners

1. ZAG may be beneficial for preventing high-fat-diet-induced hepatic lipid metabolic disorders.

2. AZGP1 is a negative regulator of fibrosis progression in kidney and heart

3. thyroid hormone (show PTH Antibodies) up-regulates the production of zinc-alpha2-glycoprotein in the liver but not in the adipose tissue.

4. Overproduction of ZAG in white adipose tissue in chronic kidney disease could be a major contributor to metabolic disturbances associated with CKD.

5. Fatty acid synthase (show FASN Antibodies) and hormone-sensitive lipase (show LIPE Antibodies) expression in liver are involved in zinc-alpha2-glycoprotein-induced body fat loss in obese mice.

6. ZAG synthesis in adipose tissue and the liver is downregulated, as are its circulating levels, in ob/ob mice.

7. Azgp1 is a possible candidate gene for regulation of body weight, elucidation of polygenic inheritance, and age-dependent changes in the genetic control of obesity.

8. Mice bearing the MAC16-tumor displayed substantial losses of body weight and fat mass, which was accompanied by major increases in ZAG mRNA and protein.

9. Glucocorticoids stimulate lipolysis through an increase in azgo1 expression, and they are responsible for the increase in azgp1 expression seen in adipose tissue of cachectic mice.

10. results suggest that EPA may preserve adipose tissue in cachectic mice by downregulation of ZAG expression through interference with glucocorticoid signalling

Human alpha-2-Glycoprotein 1, Zinc-Binding (AZGP1) interaction partners

1. Our study reveals that reduced AZGP1 expression correlates with in vitro cellular migration and invasion. In vivo, it is associated with higher metastatic risk and shorter survival in patients with soft tissue sarcomas

2. results indicate that changes in the circulating level of S100A1 (show S100A1 Antibodies) protein occur in metabolic syndrome patients; the strong correlation between serum zinc-alpha2-glycoprotein and S100A1 (show S100A1 Antibodies) might suggest that production or release of these two proteins could be related mechanistically

3. Study reports expression of Zinc-alpha2-glycoprotein (ZAG) in neurons. The level of ZAG was lower in temporal lobe epilepsy patients and time-dependently decreased in PTZ-treated rats. In addition, ZAG was shown to interact with p-ERK (show EPHB2 Antibodies) and TGF-beta (show TGFB1 Antibodies). ZAG was found to be synthesized in neurons, and both the AZGP1 mRNA and ZAG protein levels were decreased in epilepsy patients and rat models.

4. Our study provides prospective phase III validation that absent/low AZGP1 expression provides independent prognostic value in PC

5. This study demonstrated that differential expression of zinc-alpha-2-glycoprotein (AZGP1) was detected in the serums of Alzheimer's Disease patients compared with healthy controls

6. ZAG has the potential to alleviate hepatosteatosis, making it a promising therapeutic target for fatty liver.

7. we found that AZGP1 inhibited cell migration and invasion through the regulation of the PTEN/Akt (show AKT1 Antibodies) and CD44s pathways. Collectively, our findings revealed the molecular mechanism of AZGP1 expression in HCC (show FAM126A Antibodies), providing new insights into the mechanisms underlying tumor progression.

8. Absent or weak expression of AZGP1 protein was associated with worse recurrence free survival (RFS), disease specific survival, and overall survival after radical prostatectomy for prostate cancer.

9. Absent alpha-2-glycoprotein 1 zinc-binding(AZGP1) expression is an independent predictor of biochemical relapse in margin-positive localized prostate cancer and is associated with increased prostate cancer-specific mortality

10. Data show increased levels of lysozyme C (LYZ), lacritin (LACRT) and zinc-alpha-2 glycoprotein 1 (AZGP1) in pooled tear fluid sample from Graves' disease (GD) patients with moderate-to-severe Graves' orbitopathy (GO) compared with GD patients without clinical signs of GO.

Cow (Bovine) alpha-2-Glycoprotein 1, Zinc-Binding (AZGP1) interaction partners

1. Polymorphisms in the AZGP1 gene were associated with growth traits.